DotBio

Singapore, Singapore

DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies.

$5.6M raised

Aug 2023

Seed

Top Investors

Gaorong CapitalEnterprise SingaporeProx VenturesAIM-HI Accelerator Fund

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has DotBio raised?

DotBio has raised $5.6M in total funding. The most recent round was Seed. The last funding was announced in August 2023.

Who are DotBio's investors?

DotBio's investors include Gaorong Capital, Enterprise Singapore, Prox Ventures, AIM-HI Accelerator Fund.

Where is DotBio headquartered?

DotBio is headquartered in Singapore, Singapore.

What does DotBio do?

DotBio develops multi-functional antibodies based on its proprietary DotBody technology as the next generation of cancer therapies.

What stage is DotBio at?

DotBio is at the Seed stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated August 7, 2023.

MLA

"DotBio — Funding & Investors." VCBacked, August 7, 2023, https://www.vcbacked.co/company/dotbio. Accessed June 4, 2026.

APA

VCBacked. (2023). DotBio — Funding & Investors. Retrieved June 4, 2026, from https://www.vcbacked.co/company/dotbio

Wikipedia (cite web)

{{cite web |title=DotBio — Funding & Investors |url=https://www.vcbacked.co/company/dotbio |website=VCBacked |access-date=June 4, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated August 7, 2023.